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The nucleus accumbens septi (NAS) of the
forebrain has been studied by our group starting
from clinical evidences regarding perceptual dys-
functions in schizophrenia (1-3). These clinical and
experimental conjunct of findings led to a reinter-
pretation of the pathophysiology of schizophrenia
and its nuclear symptoms (4-10). There are convinc-
ing evidences regarding the role of NAS in cognitive
phenomena, such as acquisition in the process of
perception and learning (11-15), and they have been
related to the pathophysiology of schizophrenia (6,
9, 10). 
The presence of opioid receptors in the NAS
has been observed to regulate dopaminergic activity.
Intracerebroventricular administration of specific
opioid receptor agonists has shown that activation of
the opioid µ receptor located in the same NAS or in
the ventral tegmental area (16, 17) increases the
extracellular concentration of dopamine in the NAS,
measured by microdialysis. Given the role of NAS
in anxiety (13), the present experiment sought to
study the role of opioidergic transmission within the
NAS measuring its behavioral consequences.
SUBJECTS, MATHERIAL AND METHODS
Subjects
In present experiment, 90-day Holtzman strain
rats weighing 240-270 g, maintained under con-
trolled conditions of temperature (22-24OC) and light
(lights between 5:00 p.m. to 7:00 p.m.) were used.
Food for rats and water were available ad libitum.
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Abstract: Nucleus accumbens septi (NAS) is studied because its relations with cognition and anxiety. Its phar-
macological manipulation is widely used in experimental psychopathology to reproduce psychotic signs and
symptoms in animal models. In the present study, the effect of the injection of an agonist and a µ-receptor
antagonist in this structure is assessed. Holtzman strain male rats (240-290 g) were cannulated bilaterally in
NAS. One week after the injection they were subjected to an anxiety test, prior saline injection (controls),
DAMGO ([D-Ala2, N-MePhe4, Gly-ol]-encephalin, opioid agonist) or naloxone (opioid antagonist). We eval-
uated the set of parameters classically considered in our laboratory (open arm time, time per entry, open arm
entries, closed arm entries, open/closed arm quotient, open and closed arm ends arrivals, rearing, fecal bowls
and grooming behaviors. There was only a significant increase in the length of stay in the open arm with the
injection of DAMGO (0.2 µg/1 µL, p < 0.05) and a significant increase in grooming behaviors with naloxone
(1 µg/1 µL, p < 0.001), compared with saline controls (1 µL). We conclude that the receptor stimulation in NAS
generates effects compatible with anxiolysis, and blocking of such receptor in said structure results in an
increase in grooming behaviors.
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Surgery
The animals were anesthetized with ether and
stereotactically implanted with stainless steel cannu-
lae bilaterally in NAS. The cannulas (15 mm) have
a removable stylet to prevent clogging. After sur-
gery, the animals were housed in individual boxes
and maintained without disturbances for a recovery
period of one week.
Drugs
DAMGO (opioid agonist, Handa et al., 1981;
0.2 mg/1 mL) and naloxone (opioid antagonist, 1
mg/1 mL) injected into the NAS dissolved in saline
were used. The control group was injected with
saline (1 mL). 
Plus maze test
Apparatus
The plus-maze is a wooden apparatus formed
by four arms, two open and two closed, opposite
each other. The four arms are 50 cm long and 10 cm
wide. The appliance is raised 50 cm from the floor.
The closed arms have walls of 50 cm. 
Test
The animals were injected 15 min before start-
ing. After this period, the test starts and the duration
of the test was 5 min. During the test the following
parameters were considered: time in the open arm,
total number of entrances to both arms, entrances to
the open arm, entrances to the closed arm, prefer-
ence quotient (entries in the open arm/entries in the
closed arm, open/closed arm quotient), the
time/entrance ratio in the open arm, aerial explo-
ration, arrivals at the end of the open arm, grooming
and fecal boli. 
Histology
After test, rats were sacrificed with an ether
excess. Brains were removed and fixed in formalde-
Figure 1. Location of the injection site is shown in frontal brain sections. All animals considered had correct cannula placements. ●:
Cannulae placements (Pellegrino et al. 1979)
Effects of single injection of naloxone and damgo within nucleus... 207
hyde solution (20%). Five days later, brains and
position of the cannula were observed (18).
Location of the injection site was observed and
translated to frontal brain section graphics. All ani-
mals considered had correct cannula placements. 
Data analysis
Significance was studied using the ANOVA
test followed by the Student-Newman-Keuls test. In
all cases a value of p < 0.05 (two tails) was consid-
ered significant. Results are reported as means and
standard error of the mean (SEM). 
Bioethical Considerations
Bioethical and legal dispositions were consid-
ered in present experiments. Project approval crite-
ria of the National University of Cuyo were fol-
lowed, and legal aspects fulfilled. In all cases, guide-
lines set established by European Community
Council (Directive 86/609/EEC) were respected. 
RESULTS
ANOVA showed significant differences
between the groups in the time spent in the open arm
(F 2.57 = 4.42, p < 0.05). A significant increase in
the time spent in the open arm was observed with
the injection of DAMGO (0.2 µg/1 µL, p < 0.05 vs.
saline and naloxone). In the grooming behaviors,
significant differences were observed between the
groups in the time of permanence in the open arm (F
2.56 = 13.54, p <.0.0001), with a significant increase
in grooming behaviors with naloxone (1 µg/1 µL, p
< 0.001 vs. saline and DAMGO). 
DISCUSSION
Injection of drugs related to opioidergic trans-
mission in NAS produces behavioral effects in the
plus-maze test. The time spent in the open arm was
increased by DAMGO injection (Fig. 2, top). This
could be indicating that the stimulation of the µ opi-
oidergic receptors would mediate anxiolytic effects.
On the other hand, the antagonism of the same ones
using naloxone induces an increase of the grooming
behaviors (Fig. 2, bottom). The fact that the other
parameters have not been modified by the treatment
(see Table 1) can be considered a sign of the relia-
bility of the method used. However, an interaction
between opioidergic receptors and other types can
Figure 2. Top: Exploration time in open arm after saline (SAL the injection (1 µL, n = 17), naloxone (1 µg/1 mL, n = 23) and DAMGO
(0.2 µg/1 µL, n = 20). Bottom: Grooming behavior after saline injection (1 µL, n = 17), naloxone (1 µg/1 µL, n = 23) and DAMGO (0.2
µg/1 µL, n = 20). The results are shown as the mean ± standard error of the mean (SEM, * = p < 0.05, *** = p < 0.01)
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not be excluded. In this sense, as previously men-
tioned, opioidergic receptor agonists increase the
concentration of dopamine (DA) in NAS, either by
action in this structure or by action on ventral
tegmental area (16, 17). 
Something similar has been suggested for other
opioidergic receptors. Thus, the dopamine-releasing
action observed with fentanyl in NAS was induced
both by systemic administration and by selective
injection in ventral tegmental area or NAS. In the
cited study, various manipulations have been made
to act on the effect induced by fentanyl by injection
into the NAS. This was abolished by the systemic
administration of naloxone. It was also abolished by
administration into the NAS of a D-Phe-Cys-Tyr-D-
Trp-Om-Thr-Phe-Thr-NH2 antagonist in a dose-
dependent manner. Administration of a non-selec-
tive δ-opioid receptor antagonist, natrindol, also
abolished the effect of fentanyl in a dose-dependent
manner. Differential effects were observed when
selective δ receptor antagonists were used. When
blocking the effect of fentanyl on NAS with nal-
triben, a δ2-opioid receptor antagonist, blockade was
observed. This did not occur using (E)-7-benzylide-
nenaltrexone, a δ1-opioid receptor antagonist. All of
this has led to the suggestion that there is a close
interaction between opioid receptor subtypes to
modulate DA levels within the NAS. Again, the
NAS here shows its relevance in anxiety processing,
as previously described by us (13, 19). In this sense,
the present study has a character of confirmation.
The behaviors deployed in this experiment merit dif-
ferential attention. 
Grooming behaviors have been the subject of
study by our team. Several endogenous ligands may
increase it (20, 21). Some of them, such as corti-
cotropin releasing hormone (CRH) may increase it,
and may, in turn, induce an anxiogenic type frame
(20, 21). However, what we observe in this study is
an increase of the grooming behaviors with a
decrease of the anxiety, evidenced in the increase of
the time spent in the open arm. This leads to an alter-
native hypothesis for the explanation of this behav-
ior. 
One possibility is given by a possible increase
in cutaneous sensitivity due to changes in sensory
processing induced by the application of naloxone.
The action of opiates has been classically related to
the management of pain sensitivity. However, the
present findings may be indicating a modulatory
action of tactile epicritic sensitivity. This may well
be exercised on the NAS, given the concentration of
opiate receptors present in it, and the fact that this
structure has been involved in sensory processing.
In fact, a corticosteroid system has been proposed in
pain processing (22). This system, consisting of the
ventromedial prefrontal cortex and the NAS, has
been linked to chronic pain but also to another sen-
sory modality, such as tinnitus (22). This would
denote a central action on the processing of non-
painful sensory information. Thus, frontal cortex
and NAS function have been proposed as part of a
central gatekeeping system, which would filter more
than one sensory modality by assessing the affective
value and relevance of the stimuli (22).
The NAS also seems to process other sensory
modalities. Thus, the interference of their function
has been shown to interfere with the formation and
consolidation of the taste memory (23, 24). This
interference has been performed on both the mus-
carinic and glutamate receptor systems (23) and by a
protein synthesis inhibitor applied to the NAS shell
(24). Finally, it has been reported that the tactile skin
stimulation produces an increase in DA release in the
Table 1. Values of open arm entries, closed arm entries, open/closed arm quotient, time per entry, extreme open arm arrivals, extreme
closed arm arrivals, rearing and fecal boli. Rat groups: saline control (1 µL, n = 17), Naloxone (1 µg/1 µL, n = 23) and DAMGO (0.2 µg/1
µL, n = 20). Data are presented as the mean ± SEM. 
Sal Naloxone DAMGO
n = 17 n = 23 n = 20
Open arm entries 2.12 ± 0.33 2.61 ± 0.27 2.85 ± 0.49
Closed arm eEntries 5.35 ± 0.60 6.00 ± 0.71 5.50 ± 1.13
Open / Closed arm quotient 0.49 ± 0.07 0.58 ± 0.10 1.22 ± 0.39
Time per entry 16.56 ± 2.63 29.62 ± 12.36 64.84 ± 23.26
Extreme open arm arrivals 1.53 ± 0.32 1.74 ± 0.35 1.45 ± 0.41
Extreme closed arm arrivals 5.76 ± 0.57 5.78 ± 0.74 5.20 ± 1.12
Rearing 8.47 ± 1.04 5.65 ± 1.13 6.05 ± 1.16
Fecal boli 1.23 ± 0.53 1.04 ± 0.34 0.95 ± 0.28
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NAS (25). This latter finding would explain the func-
tion of the NAS system in the reaction, linking the
tactile processing to this structure and giving reason
to the groming behaviors, possibly secondary to an
increase in the corporal tactile sensibility. 
Opioids have been implicated in the patho-
physiology of schizophrenia (26). In particular, De
Wiedís work, with a passive avoidance test, was
pioneering and relevant at this point (27). In the
present study, opiates were injected directly into the
NAS, a structure traditionally linked to schizophre-
nia (see 6, 9, 10). The purpose was to study its
effects in an anxiety test, continuing findings from
other groups that cite our work (28). It is possible
that new therapeutic strategies may become of the
present findings. In fact, opioid peptides have also
been implicated in possible therapeutic uses in
schizophrenic psychoses (29). 
We may conclude that µ receptor stimulation
in NAS generates effects compatible with anxioly-
sis, and blocking of such receptor in said structure
results in an increase in grooming behaviors. The
role of opioid receptors in the NAS, and their behav-
ioral relevance, becomes evident and clinical pro-
jections may be relevant.
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